Skip to content

Comparison of three diagnostic methods to assess albendazole efficacy

Comparison of three diagnostic methods to assess albendazole efficacy: a cross-sectional parasitological survey

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN90088840
Enrollment
300
Registered
2009-10-01
Start date
2009-09-27
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soil-transmitted helminthiasis (ascariasis, hookworm disease, trichuriasis) Infections and Infestations Ascariasis

Interventions

Each day, a total of 20 children will be enrolled. They are invited to provide a single stool sample that will be subjected to three different diagnostic methods. After stool collection, each child wi
each child will be administered albendazole (400 mg).

Sponsors

Ivo de Carneri Foundation (Italy)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Child judged healthy by study physician 2. Written informed consent provided by child's parent or guardian 3. Provision of stool sample 4. No recent history of anthelminthic treatment (drugs administered within the past 2 weeks) 5. School-aged children between 5 and 16 years (although in some cases this can go as high as 20 years), either sex

Exclusion criteria

Exclusion criteria: 1. Too sick to attend school or participate in the study (e.g. severe diarrhoea, severe anaemia, high fever, etc.) 2. No parental/guardian's permission to participate (absence of written informed consent) 3. Do not provide a stool sample 4. Recent history of anthelminthic treatment (drugs administered within the past 2 weeks)

Design outcomes

Secondary

MeasureTime frame
Measured at three weeks post-treatment follow-up: 1. Agreement between diagnostic tests for prevalence and infection intensity estimates 2. Negative predictive value

Primary

MeasureTime frame
Sensitivity of diagnost test, measured at three weeks post-treatment follow-up

Countries

Tanzania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 23, 2026